LD
EXAS

Lipe & Dalton’s Exact Sciences EXAS Stock Holding History

Lipe & Dalton’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,320
Closed -$317K – 92
2025
Q1 		$317K Sell
7,320
-700
-9% -$35.4K 0.18% 68
2024
Q4 		$451K Sell
8,020
-1,000
-11% -$62.2K 0.24% 62
2024
Q3 		$614K Hold
9,020
– – 0.31% 58
2024
Q2 		$381K Buy
9,020
+1,750
+24% +$96.3K 0.2% 67
2024
Q1 		$502K Buy
7,270
+1,800
+33% +$114K 0.26% 65
2023
Q4 		$405K Buy
5,470
+400
+8% +$26.2K 0.22% 66
2023
Q3 		$346K Buy
5,070
+550
+12% +$46.7K 0.21% 68
2023
Q2 		$424K Buy
4,520
+750
+20% +$58.5K 0.24% 67
2023
Q1 		$256K Sell
3,770
-500
-12% -$32.1K 0.15% 72
2022
Q4 		$211K Buy
4,270
+100
+2% +$4.09K 0.12% 74
2022
Q3 		$135K Buy
4,170
+500
+14% +$20.6K 0.08% 80
2022
Q2 		$145K Buy
+3,670
New +$196K 0.08% 82
2020
Q2 		– Sell
-6,470
Closed -$375K – 101
2020
Q1 		$375K Buy
+6,470
New +$525K 0.32% 50

Other funds holding EXAS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Lipe & Dalton's EXAS Position: Q2 2025 in Review

Lipe & Dalton sold out of Exact Sciences (EXAS) in Q2 2025, closing a stake of 7,320 shares — an estimated $317K sold.

Lipe & Dalton first reported a position in EXAS in Q1 2020 and held it in 13 quarters. The position peaked at $614K in Q3 2024. 557 funds tracked by Wall St. Rank hold EXAS as of Q2 2025.

  • Lipe & Dalton reported no remaining Exact Sciences position as of Q2 2025 after selling out during the quarter.
  • Lipe & Dalton sold 7,320 Exact Sciences shares in Q2 2025, an estimated $317K.
  • Lipe & Dalton first reported a position in Exact Sciences in Q1 2020 and held it in 13 quarters.
  • Lipe & Dalton's Exact Sciences position peaked at $614K in Q3 2024.
  • 557 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2025.

Based on Lipe & Dalton's 13F filing for Q2 2025, filed 1 Aug 2025.